Technical Analysis for KMDA - Kamada Ltd.

Grade Last Price % Change Price Change
grade C 5.41 -2.17% -0.12
KMDA closed down 2.17 percent on Friday, August 23, 2019, on 48 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical KMDA trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.17%
Crossed Above 20 DMA Bullish -2.17%
Doji - Bearish? Reversal -2.17%
Outside Day Range Expansion -2.17%
Up 3 Days in a Row Strength -2.17%
Up 4 Days in a Row Strength -2.17%
Up 5 Days in a Row Strength -2.17%

Older signals for KMDA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Kamada Ltd., a biopharmaceutical company, develops, produces, and markets therapeutics based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases; Heparin Lock Flush to maintain potency of intravenous injection device; Kamacaine 0.5%, a spinal and epidural anesthesia; and Albumin for therapeutic plasma exchange and hypovolemic shock. In addition, the company offers Factor IX for treatment of bleeding episodes and to maintain plasma factor IX levels; Factor VIII, VWF for the treatment of bleeding episodes to maintain plasma factor VIII level, vonwillebrand disease; and Human Transferrin for in vitro and diagnostic use. Its development stage products include Aerosolized AAT, which is in Phases II-III clinical trials for alpha-1 antitrypsin deficiency, and under Phase II clinical trial for bronchiectasis, as well as completed Phase II clinical trial for cystic fibrosis; Human Transferrin for pharmaceutical use; and snake antiserum for snake bites. The company has a collaboration partnership with PARI for the development of an aerosolized AAT treatment. Kamada Ltd. sells its products through distributors worldwide, as well as is involved in marketing of imported complementing products in Israel. The company was founded in 1990 and is headquartered in Ness Ziona, Israel.
Medicine Biopharmaceutical Anatomy Cystic Fibrosis Blood Cardiac Surgery Antitrypsin Deficiency Blood Products Coagulation System Coagulation Alpha 1 Antitrypsin Bronchiectasis Heparins Immune Thrombocytopenic Purpura
Is KMDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.7
52 Week Low 4.63
Average Volume 30,923
200-Day Moving Average 5.5631
50-Day Moving Average 5.61
20-Day Moving Average 5.502
10-Day Moving Average 5.3905
Average True Range 0.1637
ADX 22.59
+DI 14.3549
-DI 25.9681
Chandelier Exit (Long, 3 ATRs ) 5.3689
Chandelier Exit (Short, 3 ATRs ) 5.6011
Upper Bollinger Band 5.7736
Lower Bollinger Band 5.2304
Percent B (%b) 0.33
BandWidth 9.872774
MACD Line -0.0809
MACD Signal Line -0.0805
MACD Histogram -0.0004
Fundamentals Value
Market Cap 202.33 Million
Num Shares 37.4 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -108.20
Price-to-Sales 2.15
Price-to-Book 2.76
PEG Ratio 9.35
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.63
Resistance 3 (R3) 5.64 5.57 5.59
Resistance 2 (R2) 5.57 5.52 5.57 5.58
Resistance 1 (R1) 5.49 5.48 5.46 5.48 5.57
Pivot Point 5.43 5.43 5.41 5.42 5.43
Support 1 (S1) 5.35 5.37 5.32 5.34 5.25
Support 2 (S2) 5.28 5.34 5.28 5.24
Support 3 (S3) 5.20 5.28 5.23
Support 4 (S4) 5.19